secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0000950170-25-088752
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana reports positive six-month data for islet cell therapy in type 1 diabetes without immunosuppression
--------------------------------------------------------------------------------

- Six-month results: transplanted allogeneic islet cells (UP421) safe, survive, evade immune system, produce insulin without immunosuppression.
- C-peptide detectable fasting and increases with mixed meal tolerance test, confirming insulin secretion; MRI shows graft survival at 6 months.
- No safety issues; HIP-modified cells evade both allogeneic and autoimmune responses in type 1 diabetes patient.
- Sana plans to file IND for SC451 (stem cell-derived HIP islet therapy) as soon as next year, incorporating UP421 learnings.
- Data presented at ADA 85th Scientific Sessions; study funded by Helmsley Charitable Trust, partnership with Uppsala University Hospital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000095017025088752/0000950170-25-088752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000095017025088752/sana-20250623.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-088752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer